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Retiform hemangioendothelioma (RH) is an infrequently encountered vascular neoplasm of intermediate or borderline
malignancy. Treatment of RH is controversial. We present a case of a 44-year-old Asian male presenting with an unresectable RH
of the pelvis. The patient was treated with concurrent low-dose Cisplatin and External beam Radiation (4140cGy in 180cGy per
fraction).Thisistheﬁrstreportofaclinicalcompleteresponseandalong-termlocalcontrolofthisraretumor.Thishassigniﬁcant
clinical implication, since it gives the ﬁrst evidence of treatment of this rare tumor using concurrent low-dose chemotherapy and
radiation.
1.Introduction
Retiform hemangioendothelioma (RH) is an infrequently
encountered vascular neoplasm of intermediate or border-
line malignancy. Treatment of RH is controversial though
most reports have described surgical resection followed by
adjuvant radiation (RT) with or without chemotherapy. We
describe a case report of a 44-year-old Asian male presenting
with an unresectable RH of the pelvis and successful treated
with concurrent chemotherapy and radiation.
2.CaseReport
A 44 year old male presented with one year history of
slowly enlarging tumor of the right medial thigh and
scrotum and extending to the left groin (Figure 1(a)). The
lesion was asymptomatic in the beginning and the skin
was intact. Gradually the skin over the right inguinal
area eroded and the lesion started causing discomfort
which became progressively worse. The patient’s previous
medical history wasunremarkable.Laboratory examinations
including HIV status were normal. MRI of the right hip
showed abnormal ﬂuid-like density ill-deﬁned in nature in
the anterior right groin anterior to the pectineus muscle
and dissecting into the medial proximal right thigh. There
was no clinical or radiological evidence of regional lymph
node involvement. Computed tomography scans of the chest
and abdomen showed no evidence of metastatic disease.
Histological examination of the biopsy specimen revealed
numerous anatomizing vascular channels in the dermis.
The vascular channels were composed of endothelial cells,
some of which had a hobnail appearance. ICC stain for
CD31 was positive and HHV8 was negative. Histological
diagnosis of hemangioendothelioma with retiform features
was established. The patient was initially evaluated for
surgical resection but was deemed unresectable because of
extent of the disease. A decision was made to treat the patient
with chemoradiation and reevaluation after 4140cGy. A 3-
dimensional plan was generated to treat the pelvis, after
contouring the Gross tumor (based on pretreatment CT
and MR images) plus a 2cm margin (Figures 1(b) and
1(c)). A total dose of 4140cGy in 180cGy per fraction was
delivered with an intention of attempt at surgical resection.
Weekly Cisplatin (30mg/m2) was given concomitantly with
radiation. The patient tolerated the treatment well and had
an excellent clinical response (Figure 1(d)). Reevaluation2 Sarcoma
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Figure 1: A 44-year-old male presenting with advanced RH of the pelvis and groin (a) Prior to treatment, arrow showing the extensive area
of discoloration and skin breakdown (b) Anteroposterior (A-P) RT ﬁeld (c) Lateral RT ﬁeld (d) Groin in the last week of RT showing good
clinical response (arrow) though skin break down persists probably secondary to RT. The skin healed within 4–6 weeks of completion of RT.
at 4140cGy revealed a minimal radiological response and
it was decided to abort treatment at the time because of
tumor unresectibility. The patient was followed with a repeat
biopsy 8 weeks after RT. Biopsy showed an excellent response
but some residual disease. However, a 6-month followup
revealed a complete clinical response. The patient has been
disease-free at 36 months.
3. Discussion
Retiform hemangioendothelioma (RH) is an infrequently
encountered vascular neoplasm of intermediate or border-
line malignancy that has been classiﬁed as a distinct type of
low-grade cutaneous angiosarcoma. Up to date, a total of 25
cases were described in the literature [1–11]. First, ﬁfteen
cases were described by Calonje et al. in 1994 [1]. It has
been proposed by Calonje that in the past examples of the
tumor he designated as RH have been diagnosed as angiosar-
coma. It is important to distinguish RH from cutaneous
angiosarcoma (CA) as the clinical course is quite diﬀerent.
CA can arise in the context of lymphedema (Stewart-Treves
syndrome) so can RH (see above) and can be radiation-
induced. Cutaneous angiosarcoma has high incidence of
recurrence and metastasis and overall carries poor prognosis
with high mortality. In comparison, RH has a high local
recurrence rate, however, rarely metastasizes and there have
been no tumor-related deaths reported up to date [1–11].
Histology is the only way to reliably diﬀerentiate RH from
CA. Histologically, in CA, the inﬁltrative pattern is much
more disorganized, with sinusoidal or sieve collagen bundles
and vascular spaces are more irregular and jagged. Most
importantly, even in well-diﬀerentiated CA, mitotic ﬁgures,
cytologic atypia, variation in cellular size, and multilayering
canbefound[1,12],whilethereisalmostnocytologicatypia
and no mitotic activity in RH.
Morphologically, RH presents as exophytic mass or
nodule or a plaque, dermal or subcutaneous, that grows
slowly. Most tumors present in young to middle-aged adults
(Range 9–78 years) [2]. Most lesions are single though one
case of multiple tumors developing in diﬀerent anatomic
sites (trunk and extremities) has been described [3]. One
case of regional lymph node metastasis [1] and one soft-
tissue metastasis has been reported [4]. There is female
predominance 2:1 with size range of 1 to 30cm. Duration of
the disease ranged from 2 months to several years. No distant
metastasesortumor-relateddeathshavebeenreported;how-
ever, RH recurs in almost half of the cases. Often, multiple
recurrences are observed. Recurrences are observed ranging
from months to several years after original presentation. Eti-
ology is unknown; however, an association between RH and
human herpes virus type 8 [6], lymphedema [1], previous
radiotherapy [1, 6], and noncutaneous malignant neoplasms
[1, 6, 7, 11] has been reported but not clearly established.
Clinically, RH lesions could be located in the dermis
(predominantly) with extension into the subcutaneous tis-
sues or striated muscle as was also reported as in our case
[1]. A characteristic microscopic feature is the presence of
elongated, arborizing, thin-walled blood vessels extending
between collagen bundles in a retiform pattern, reminiscent
of the architecture of normal rete testis [1]. In some areas,
a prominent lymphocytic inﬁltrate is present. Some areas
of the tumor are solid and are composed of epitheloid
or spindle cells and dilated vascular channels sometimes
with intraluminal papillary projections. Cytologic atypia is
minimal and few or no mitotic ﬁgures are seen [1, 7].
Immunohistochemically, neoplastic cells are positive for CD
31, CD 34, factor VIII-related antigen, and bound Ulex
earopaeus agglutinin (UEA) (7). The spindle cells are positive
for UEA-1 and CD 31 but not for FVIII-Rag and CD34 [1].
RH may rarely express D2-40, but it does not usually express
VEGR-3, markers of endothelium of lymphatic vessels [13].
In summary, based on the staining patterns, it has been
s u g g e s t e dt h a tR Hi sav a s c u l a re n t i t yw h i c hu s u a l l yd o e sn o t
have lymphatic diﬀerentiation [13].
Other vascular tumors that morphologically can present
similarly to RH and need to be diﬀerentiated from
RH include Dabska’s tumor, lymphoma, dermatoﬁbrosar-
coma protuberans, hemangioma, bacillary angiomatosis,Sarcoma 3
cutaneous metastases, blue-rubber bleb nevus syndrome,
Kaposi’s sarcoma, targetoid hemosiderotic hemangioma,
hobnail hemangioma, epitheloid hemangioendothelioma,
and polymorphous hemangioendothelioma of lymph node
[1,2,7,9].Eventhoughsomehistologicaloverlapexists,each
of the neoplasms has their unique features [1, 2, 8].
Treatment of choice for RH has been surgical excision
with histopathologically tumor-free margins. In the cases
reported up to date, patients were treated initially by surgical
excision. Approximately 50% of the cases recurred [1–
13]. Amputation of hand, disarticulation of toe, partial
penectomy, and amputation of ﬁnger has been described [1].
Radiotherapy has been reported to be successfully adminis-
tered as adjuvant treatment for local as well as regional nodal
RHrecurrences[1,6].Inaddition,adjuvantimmunotherapy
with recombinant interferon alpha has been tried. As per
our knowledge, our report is the ﬁrst reported successful
treatment of RH with low-dose cisplatin and moderate
RT without surgical resection. Successful treatment of this
uncommon tumor remains under investigation.
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